Page 1

Six - month interim report ( Q2 ) 2026 ( unaudited ) ALK Company release No 12/2026 ALK delivers 18 % organic revenue growth with operating profit ( EBIT ) up 19 % in Q2 ALK sustained strong momentum in Q2 , with double - digit growth across all regions driven by sales of tablets and anaphylaxis products . Operating profit increased by 19 % on sales growth and an improving gross margin , partly offset by increasing investments in R & D and sales and marketing . For the first six months , the EBIT margin was 28 % . The full - year revenue outlook has been updated . Performance highlights ( Q2 ) Comparative figures for Q2 2025 are shown in brackets . Growth rates are stated in local currencies ( I.c. ) , unless otherwise indicated . ་ ་ Revenue increased by 18 % to DKK 1,795 million ( 1,527 ) on double - digit growth across regions , driven by sales of tablets and anaphylaxis products . Tablet sales grew by 22 % to DKK 1,013 million ( 831 ) , well - supported by the paediatric roll - out , with 27 % growth in Europe , 17 % in North America , and International markets returning to growth at 9 % . SCIT / SLIT drop sales were up 7 % to DKK 515 million ( 481 ) , mainly driven by SCIT shipments to China . Sales of Anaphylaxis & other products increased by 26 % to DKK 267 million ( 215 ) , largely boosted by Jext® . Operating profit ( EBIT ) increased by 19 % to DKK 445 million ( 375 ) with an unchanged EBIT margin of 25 % ( 25 % ) , as gross margin improvements were offset by strategic investments , mainly in sales and marketing . Free cash flow was DKK 218 million ( 216 ) and was impacted by fluctuations in working capital ( timing of payments ) . CAPEX was DKK 71 million ( 104 ) . Free cash flow for the first six months increased to DKK 889 million ( 546 ) , and the net debt to EBITDA ratio was negative at 0.6 . Financial highlights Growth Growth In DKKm Q2 2026 I.c. r.c. H1 2026 I.c. r.c. Revenue 1,795 18 % 18 % 3,566 18 % 17 % EBIT 445 19 % 19 % 1,015 20 % 20 % EBIT margin - % 25 % 28 % I.c .: local currency ; r.c .: reported currency Allergy + strategy highlights ་ Planning for phase 3 development of the peanut tablet continued with trial initiation still expected in late 2026. Dialogues with regulatory authorities are ongoing . New approvals and launches for neffyⓇ nasal adrenaline spray : now launched by ALK in Canada and 5 additional European markets , bringing the total number of markets launched to 10 . In the UK , paediatric use of ACARIZAX® and ITULAZAX® was recently recommended by the National Institute for Health and Care Excellence ( NICE ) for admittance to the public healthcare system with general reimbursement . 2026 full - year outlook The full - year revenue outlook has been updated reflecting a strong underlying momentum for tablet sales and reduced risks associated with price and rebate adjustments in 2026 . ་ ་ Revenue is now expected to grow by 14-16 % ( previously 13-16 % ) in local currencies , based on growth across all sales regions and product lines . The EBIT margin is still expected at around 26 % . Commenting on the Q2 results , CEO Peter Halling said : " ALK's continued double - digit growth in Q2 reflects the strength of our strategy and our firm commitment to improving the lives of people impacted by allergy worldwide . The paediatric roll - out is increasingly fuelling tablet growth , new launches of neffyⓇ are underway , and the confirmation of our plans to initiate phase 3 development of the peanut tablet underscores ALK's scientific capabilities . We remain well - positioned to continue delivering sustainable value to patients and caregivers . " Page 1 of 16 Company release No 12/2026 - 20 August 2026 ALK - Abelló A / S - Bøge Allé 6-8 - DK - 2970 Hørsholm - Denmark - www.alk.net Tel +45 4574 7576 - CVR No 63 71 79 16 - LEI code : 529900SGCREUZCZ7P020